mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.097 |
0.009 |
mRNA |
selumetinib:BRD-A02303741 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.09 |
0.01 |
mRNA |
5-FU |
CTRPv2 |
pan-cancer |
AAC |
0.086 |
0.01 |
mRNA |
selumetinib:piperlongumine (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.089 |
0.01 |
mRNA |
L-685458 |
CTRPv2 |
pan-cancer |
AAC |
0.092 |
0.01 |
mRNA |
Mitomycin-C |
CTRPv2 |
pan-cancer |
AAC |
0.082 |
0.01 |
mRNA |
Erlotinib |
gCSI |
pan-cancer |
AAC |
0.14 |
0.01 |
mRNA |
ML320 |
CTRPv2 |
pan-cancer |
AAC |
0.085 |
0.02 |
mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.086 |
0.02 |
mRNA |
YM-155 |
CTRPv2 |
pan-cancer |
AAC |
-0.089 |
0.02 |